These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15058530)

  • 1. Infliximab infusion reactions: desensitizing ourselves to the danger.
    Persley KM
    Inflamm Bowel Dis; 2004 Jan; 10(1):62-3. PubMed ID: 15058530
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence and management of infusion reactions to infliximab: a large center experience.
    Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
    Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red man syndrome and infliximab.
    Lobel EZ; Korelitz BI; Warman JI
    J Clin Gastroenterol; 2003 Feb; 36(2):186. PubMed ID: 12544210
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapy for Crohn's disease.
    Selby W
    Intern Med J; 2001 Mar; 31(2):73-4. PubMed ID: 11480481
    [No Abstract]   [Full Text] [Related]  

  • 6. Infliximab dose intensification by shortening infusion intervals.
    Magro F; Bastos R; Marques M; Costa Santos C
    Inflamm Bowel Dis; 2008 Mar; 14(3):432-4. PubMed ID: 18022873
    [No Abstract]   [Full Text] [Related]  

  • 7. [Remicade (infliximab) in the treatment of Crohn disease].
    Brazier F; Delcenserie R; Dupas JL
    Presse Med; 2000 Sep; 29(16):1463-4. PubMed ID: 11039091
    [No Abstract]   [Full Text] [Related]  

  • 8. Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction.
    Ryan BM; Romberg M; Wolters F; Stockbrugger RW
    Eur J Gastroenterol Hepatol; 2004 Sep; 16(9):941-2. PubMed ID: 15316423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
    Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease.
    Ritz MA; Jost R
    Inflamm Bowel Dis; 2001 Nov; 7(4):327. PubMed ID: 11720324
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S36-9. PubMed ID: 11685974
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a Crohn's disease patient.
    Kato S; Kobayashi T; Kani K; Takabayashi H; Yamamoto R; Yakabi K
    Inflamm Bowel Dis; 2011 Dec; 17(12):E156-7. PubMed ID: 21898702
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab.
    McIlwain L; Carter JD; Bin-Sagheer S; Vasey FB; Nord J
    J Clin Gastroenterol; 2003; 36(5):411-3. PubMed ID: 12702983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe agranulocytosis following first infliximab infusion in Crohn's disease.
    Rosales-Zábal JM; Fernández-Pérez F; Albandea-Moreno C; Vera-Rivero FM; Navarro-Jarabo JM
    Inflamm Bowel Dis; 2011 Nov; 17(11):E147-8. PubMed ID: 21830280
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance infliximab infusions forever?
    Lee SD; Surawicz CM
    Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract]   [Full Text] [Related]  

  • 16. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged duration of response to infliximab in early pediatric Crohn's disease.
    Kugathasan S
    J Pediatr Gastroenterol Nutr; 2001 Sep; 33 Suppl 1():S40-3. PubMed ID: 11685975
    [No Abstract]   [Full Text] [Related]  

  • 18. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion.
    Riegert-Johnson DL; Godfrey JA; Myers JL; Hubmayr RD; Sandborn WJ; Loftus EV
    Inflamm Bowel Dis; 2002 May; 8(3):186-91. PubMed ID: 11979139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual presentation of tuberculosis after infliximab therapy.
    Magro F; Pereira P; Veloso FT; Carneiro F
    Inflamm Bowel Dis; 2005 Jan; 11(1):82-4. PubMed ID: 15674123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.